PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2162944-1	1990	Regulation of the neurotensin receptor-inositol phosphate-intracellular Ca2+ ((Ca2+]i) pathway was studied in HT29 cells.	Inositol Phosphates	39-57	neurotensin	Homo sapiens	18-29	
15245876-3	2004	This potentiating effect of neurotensin was blocked by inhibitors of phospholipase C and protein kinase C, was accompanied by an increase in the level of soluble inositol phosphates and did not involve an autocrine factor.	Inositol Phosphates	162-181	neurotensin	Homo sapiens	28-39	
14570823-0	2003	Ca2+ channel blockers enhance neurotensin (NT) binding and inhibit NT-induced inositol phosphate formation in prostate cancer PC3 cells.	Inositol Phosphates	78-96	neurotensin	Homo sapiens	67-69	
9851594-7	1998	Both compounds, following binding to neurotensin NT2 receptor, enhance inositol phosphates (IP) formation with a subsequent [Ca2+]i mobilisation; induce arachidonic acid release; and stimulate mitogen-activated protein kinase (MAPK) activity.	Inositol Phosphates	71-90	neurotensin	Homo sapiens	37-48	
9851594-7	1998	Both compounds, following binding to neurotensin NT2 receptor, enhance inositol phosphates (IP) formation with a subsequent [Ca2+]i mobilisation; induce arachidonic acid release; and stimulate mitogen-activated protein kinase (MAPK) activity.	Inositol Phosphates	92-94	neurotensin	Homo sapiens	37-48	
2559720-2	1989	It has previously been shown that neurotensin binds to high-affinity receptors in the adenocarcinoma HT29 cell line, and that receptor occupancy leads to inositol phosphate formation.	Inositol Phosphates	154-172	neurotensin	Homo sapiens	34-45	
2559720-8	1989	Phorbol 12-myristate 13-acetate (PMA) inhibited by 50% the neurotensin effects on both intracellular Ca2+ and inositol phosphate levels.	Inositol Phosphates	110-128	neurotensin	Homo sapiens	59-70	
3011505-1	1986	Association of neurotensin to its receptor in HT29 cells increases the intracellular concentration of inositol phosphates.	Inositol Phosphates	102-121	neurotensin	Homo sapiens	15-26	
3011505-3	1986	Half-maximal stimulation of the three inositol phosphates was obtained with 50-100 nM neurotensin.	Inositol Phosphates	38-57	neurotensin	Homo sapiens	86-97	
2826275-3	1987	The present study demonstrates that PMA and DAG augment prolactin release and attenuate the elevations of inositol phosphates (IPX) elicited by thyrotropin-releasing hormone (TRH), angiotensin II, neurotensin, bombesin and gonadotropin-releasing hormone (GnRH) in normal anterior pituitary and prolactin-secreting 7315a tumor cells.	Inositol Phosphates	106-125	neurotensin	Homo sapiens	197-208	
2995163-6	1985	The neurotensin analog [D-Trp11]-neurotensin antagonized in a concentration-dependent manner the effect of neurotensin both on prolactin release and on [3H]inositol phosphate production.	Inositol Phosphates	156-174	neurotensin	Homo sapiens	4-15	
2995163-6	1985	The neurotensin analog [D-Trp11]-neurotensin antagonized in a concentration-dependent manner the effect of neurotensin both on prolactin release and on [3H]inositol phosphate production.	Inositol Phosphates	156-174	neurotensin	Homo sapiens	33-44	
2995163-6	1985	The neurotensin analog [D-Trp11]-neurotensin antagonized in a concentration-dependent manner the effect of neurotensin both on prolactin release and on [3H]inositol phosphate production.	Inositol Phosphates	156-174	neurotensin	Homo sapiens	33-44	
2995163-9	1985	These results suggest that neurotensin action at the pituitary is mediated by the early hydrolysis of polyphosphoinositides, leading to the production of 1,2-diacylglycerol and inositol phosphates which may initiate intracellular processes responsible for hormonal release.	Inositol Phosphates	177-196	neurotensin	Homo sapiens	27-38